News

GlobalData on MSN2d
Arch Biopartners’ Phase II AKI prevention trial begins patient recruitment
Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin’s efficacy in ...
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The Company is developing a platform of novel drugs ...
Business Insider11mon
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the ...
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI) Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its ...
Nasdaq2y
Arch Biopartners Receives Funding for Development of LSALT ... - Nasdaq
--Today, Arch Biopartners Inc.,, a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and up ...
Business Insider4y
Arch Biopartners Files New Patent Application for Novel Antibody ...
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for ...
Seeking Alpha1y
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing ...
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing inflammation and acute organ injury. The Company is developing new drug candidates that inhibit inflammation in ...
Nasdaq5y
Arch Biopartners Expands the Primary Endpoint of its Phase II ... - Nasdaq
--Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has expanded the primary endpoint of the Phase ...
Morningstar3mon
Arch Biopartners Announces Toronto General Hospital Ethics Board ...
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN ...
The National Law Review2mon
Arch Biopartners Arranges Non-Brokered Private Placement
TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private ...
Morningstar11mon
Arch Biopartners’ Cilastatin Drug Candidate to ... - Morningstar
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that cilastatin, the Company’s second ...
The National Law Review4mon
Arch Biopartners Closes Non-Brokered Private Placement
TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed a non ...